Should I Buy SVA Stock in 2026?

Data-driven analysis and honest assessment for Sinovac Biotech Ltd

Analysis Updated:
HOLDMixed signals - suitable for existing holders

Current Price: $6.47P/E: 6.7

Decision Score

6.4/10

Hold

Based on 6 fundamental factors

Score Breakdown:

Valuation (20%)9/10

Very low P/E of 6.7 suggests undervaluation

Growth (20%)5/10

Slow growth of 3%

Profitability (20%)4/10

Thin margins (0% net)

Financial Health (15%)5/10

Financial health data limited

Cash Flow (15%)10/10

Excellent FCF yield of 23.9%

Insider Activity (10%)5/10

No recent insider activity

Key Investment Metrics

Current Price

$6.47

P/E Ratio

6.66

Revenue Growth

3.0%

Profit Margin

0.2%

Market Cap

$0.6B

Dividend Yield

8.50%

How SVA Compares to Competitors

Understanding how SVA stacks up against peers helps inform your investment decision.

How SVA Compares to Peers

Upcoming Events for SVA

+5 Reasons TO Buy SVA

1. Attractively valued at 6.7x earnings

strong

A P/E ratio of 6.7 is below the market average of ~20x, suggesting the stock may be undervalued.

2. High gross margins of 87%

strong

Gross margins above 50% typically indicate strong brand value or intellectual property moats.

3. High free cash flow yield of 23.9%

strong

FCF yield above 5% means substantial cash generation for dividends, buybacks, or reinvestment.

4. Attractive dividend yield of 8.5%

strong

Dividend yield above 3% provides meaningful income and signals management confidence.

-5 Reasons NOT to Buy SVA

1. Thin profit margins of 0.2%

high risk

Low margins provide little cushion against cost increases or pricing pressure.

2. Small-cap volatility risk

medium risk

Market cap under $2B means higher volatility and lower liquidity.

Who Should Buy SVA?

Investment Profile

Risk Level

Very High

Recommended Holding Period

1-3 years or long-term income

Best For:

  • Value Investors

    P/E of 6.7 offers margin of safety

  • Income Investors

    8.5% yield provides regular income

Not Suitable For:

  • Growth Investors

    Limited 3% growth may disappoint

  • Risk-Averse Investors

    Very High risk may cause uncomfortable volatility

  • Large Position Traders

    Lower liquidity may impact execution

Consider These Alternatives

If you're interested in SVA, compare these Health Care peers:

Pro tip: Compare SVA directly with competitors using our comparison tool to see which stock better fits your criteria.

Get the Full Picture

Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for SVA

Frequently Asked Questions

What is SVA stock price today?

SVA (Sinovac Biotech Ltd) stock is trading at $6.47 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is SVA stock going up or down today?

SVA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy SVA stock now?

The decision to buy SVA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is SVA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for SVA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is SVA stock overvalued or undervalued?

SVA currently trades at a P/E ratio of 6.66, which may suggest attractive valuation. Our DCF calculator provides intrinsic value estimates to help determine if SVA is fairly priced.

What is SVA's P/E ratio?

SVA has a price-to-earnings (P/E) ratio of 6.66, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is SVA's market cap?

SVA (Sinovac Biotech Ltd) has a market capitalization of $0.64 billion, making it a small-cap stock.

What is SVA's price to book ratio?

SVA trades at a price-to-book (P/B) ratio of 1.82, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Similar Investment Decisions

Explore investment analyses for stocks similar to Sinovac Biotech Ltd

Explore Categories

Disclaimer

This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.